The induced pluripotent stem cells (iPSCs), derived by ectopic expression of reprogramming
factors in somatic cells, can potentially provide unlimited autologous cells for regenerative …

Abstract Human induced Pluripotent Stem Cells (iPSCs) have enormous potential in
understanding developmental biology, disease modeling, drug discovery, and regenerative …

Induced pluripotent stem cells (iPSC)-based therapies have been hailed as the future of
regenerative medicine because of their potential to provide treatment options for most …

Adoptive T-cell immunotherapy has garnered wide attention, but its effective use is limited by
the need of multiple ex vivo manipulations and infusions that are complex and expensive. In …

Human embryonic stem cells (hESCs), initially thought to be immune privileged cells, are
now known to be susceptible to immune recognition. Human induced pluripotent stem cells …

The prospects for using autologous induced pluripotent stem cells (iPSCs) in cell
replacement therapy have been tempered by evidence that undifferentiated, syngeneic …

In 2006 Yamanaka's group showed that stem cells with properties similar to embryonic stem
cells could be generated from mouse fibroblasts by introducing four genes. These cells were …

Recent clinical trials are evaluating induced pluripotent stem cells (iPSCs) as a cellular
therapy in the field of regenerative medicine. The widespread clinical utility of iPSCs is …

In currently ongoing adoptive T-cell therapies, T cells collected from the patient are given
back to the patient after ex vivo cell activation and expansion. In some cases, T cells are …

The ability to reprogram somatic cells into induced pluripotent stem cells (iPSCs) using
defined factors provides new tools for biomedical research. However, some iPSC clones …